Lazertinib Uses, Dosage, Side Effects and more
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
| Trade Name | Lazertinib |
| Generic | Lazertinib |
| Lazertinib Other Names | Lazertinib |
| Type | |
| Formula | C30H34N8O3 |
| Weight | Average: 554.655 Monoisotopic: 554.275386987 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
